CORRESP 1 filename1.htm
Ladenburg Thalmann & Co. Inc.
4400 Biscayne Blvd, 14th Floor
Miami, FL 33137
July 17, 2017
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
| Re: |
| Registration Statement on Form S-1 (Registration No. 333-218305) |
| Concurrence in Acceleration Request |
Ladies and Gentlemen:
Ladenburg Thalmann & Co. Inc. (“ Ladenburg ”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Cyclacel Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 p.m. (Eastern Time), or as soon as practicable thereafter, on July 17, 2017, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
| Very truly yours, |
|
| LADENBURG THALMANN & CO. INC. |
|
| By: |
/s/ Nicholas Stergis |
|
Name: Nicholas Stergis |
|
Title: Managing Director |